Among them, the β-defensins HBD-2 and HBD-3 are downregulated in AD, as consequence of STAT1 inhibition by SOCS1 and SOCS3, transcriptionally activated by IL-4 and IL-13 via STAT6 (83). The gene discussed is SOCS1; the disease is Alzheimer disease.